"Pharmacogenetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION).
| Descriptor ID |
D010597
|
| MeSH Number(s) |
H01.158.273.343.750 H01.158.703.052 H02.628.479
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenetics".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenetics".
This graph shows the total number of publications written about "Pharmacogenetics" by people in this website by year, and whether "Pharmacogenetics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 0 | 3 |
| 2005 | 4 | 4 | 8 |
| 2006 | 6 | 6 | 12 |
| 2007 | 7 | 1 | 8 |
| 2008 | 7 | 6 | 13 |
| 2009 | 4 | 5 | 9 |
| 2010 | 10 | 8 | 18 |
| 2011 | 6 | 5 | 11 |
| 2012 | 12 | 10 | 22 |
| 2013 | 9 | 11 | 20 |
| 2014 | 6 | 5 | 11 |
| 2015 | 7 | 4 | 11 |
| 2016 | 9 | 7 | 16 |
| 2017 | 5 | 3 | 8 |
| 2018 | 7 | 3 | 10 |
| 2019 | 9 | 4 | 13 |
| 2020 | 3 | 4 | 7 |
| 2021 | 3 | 6 | 9 |
| 2022 | 3 | 4 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacogenetics" by people in Profiles.
-
Implementation of pharmacogenomics into inpatient general medicine. Pharmacogenet Genomics. 2023 02 01; 33(2):19-23.
-
Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care. Pharmacogenet Genomics. 2022 04 01; 32(3):79-86.
-
Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy. Cancer Med. 2022 07; 11(14):2801-2816.
-
Modern developments in germline pharmacogenomics for oncology prescribing. CA Cancer J Clin. 2022 07; 72(4):315-332.
-
Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial. Anesth Analg. 2022 11 01; 135(5):929-940.
-
Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney360. 2022 02; 3(2):307-316.
-
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing. Cancer. 2022 Apr 15; 128(8):1649-1657.
-
Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform. J Appl Lab Med. 2021 11 01; 6(6):1505-1516.
-
TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results. Clin Pharmacol Ther. 2022 01; 111(1):263-271.
-
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients. Oncologist. 2021 11; 26(11):e2042-e2052.